Oregon Clinical and Translational Research Institute

OCTRI Mission

To enhance the efficiency and quality of rigorously translating research ideas into impact.

A catalyst for your translational research

We are the Oregon Clinical and Translational Research Institute. You’ll come to know us as OCTRI, pronounced “oak tree” (\ ˈōk - trē \). If you’re an investigator, regional partner or member of a study team, we’re here to support you in the critical stages of clinical and translational research.

No matter where you are in the process, we can help you remove barriers, apply best practices and translate biomedical advances into treatments.

Take the first step

OCTRI Impact

OCTRI trophy icon noting that OCTRI has earned OHSU $140 million in follow-on funding from pilot awards. Clipboard icon noting that the OCTRI CTRC has supported 842 projects. A laptop icon noting that OCTRI has enrolled over 1000 faculty, fellows, and students.

Stories of impact - listen to OCTRI podcasts

Rooted In Oregon, Episode 1: Meet our directors

OCTRI’s Director, Dr. David Ellison, and Senior Associate Director, Dr. Cynthia Morris, explain what OCTRI is and which services we provide to clinical and translational investigators.
Listen now.

Rooted In Oregon, Episode 2: Meet Dr. Rebecca Spain

Dr. Spain is a neurologist at OHSU who has utilized multiple OCTRI resources and services to advance her collaborative research on multiple sclerosis.
Listen now.

Ready to discuss your needs?

Contact an OCTRI Navigator for project guidance and support.

503-418-9790

octri@ohsu.edu

Resource request form

Innovation through CTSA hub partnership

OCTRI headquarters for multi-institution National Center for Data to Health

Since 2017, OCTRI has been a key partner in establishing and leading the multi-institution CTSA program, National Center for Data to Health (CD2H). The CD2H accelerates advancements in informatics by promoting data reuse and interoperability, tool sharing, informatics fluency, and collaboration across the entire CTSA network.

Learn about CD2H Phase III launching in 2020.